Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials
Autore:
Folts, JD; Schafer, AI; Loscalzo, J; Willerson, JT; Muller, JE;
Indirizzi:
Univ Wisconsin, Sch Med, Coronary Thrombosis Res Lab, Madison, WI 53792 USA Univ Wisconsin Madison WI USA 53792 mbosis Res Lab, Madison, WI 53792 USA Baylor Coll Med, Vet Affairs Med Ctr, Med Serv, Houston, TX 77030 USA Baylor Coll Med Houston TX USA 77030 Ctr, Med Serv, Houston, TX 77030 USA Boston Univ, Med Ctr, Dept Med, Boston, MA USA Boston Univ Boston MA USABoston Univ, Med Ctr, Dept Med, Boston, MA USA Univ Texas, Sch Med, Dept Internal Med, Houston, TX USA Univ Texas Houston TX USA s, Sch Med, Dept Internal Med, Houston, TX USA Univ Kentucky, Med Ctr, Div Cardiol, Lexington, KY 40536 USA Univ Kentucky Lexington KY USA 40536 Div Cardiol, Lexington, KY 40536 USA
Titolo Testata:
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
fascicolo: 2, volume: 33, anno: 1999,
pagine: 295 - 303
SICI:
0735-1097(199902)33:2<295:APOTPP>2.0.ZU;2-J
Fonte:
ISI
Lingua:
ENG
Soggetto:
CANINE CORONARY-ARTERIES; PLATELET THROMBUS FORMATION; ACUTE MYOCARDIAL-INFARCTION; CYCLIC FLOW VARIATIONS; STABLE ANGINA-PECTORIS; RANDOMIZED TRIAL; ENDOTHELIAL INJURY; CARDIOVASCULAR-DISEASE; CIRCADIAN VARIATION; UNSTABLE ANGINA;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
87
Recensione:
Indirizzi per estratti:
Indirizzo: Folts, JD Univ79,sconsin, Sch Med, Coronary Thrombosis Res Lab, 600 Highland Ave,H6-3 Univ Wisconsin 600 Highland Ave,H6-379 Madison WI USA 53792 H6-3
Citazione:
J.D. Folts et al., "A perspective on the potential problems with aspirin as an antithrombotic agent: A comparison of studies in an animal model with clinical trials", J AM COL C, 33(2), 1999, pp. 295-303

Abstract

Aspirin is the most widely prescribed agent to reduce the platelet-mediated contributions to atherosclerosis, coronary thrombosis and restenosis after angioplasty. While aspirin treatment has led to significant reductions inmorbidity and mortality in many clinical trials, there are several scenarios in which aspirin may fail to provide a full antithrombotic benefit. The cyclic flow model of experimental coronary thrombosis suggests that elevations of plasma catecholamines, high shear forces acting on the platelets in the stenosed lumen and the presence of multiple, input stimuli can activateplatelets through different mechanisms that may lead to thrombosis despiteaspirin therapy. Aspirin therapy is limited because it only blocks some of the input stimuli, leaving aspirin-independent pathways through which coronary thrombosis can be precipitated. These include thrombin and thrombogenic arterial wall substrates such as tissue factor. New agents that block the adenosine diphosphate (ADP) receptor, or regulate platelet free cytosolic calcium, such as direct nitric oxide donors, may be more potent overall than aspirin. Agentsthat block the platelet integrin GPIIb-IIIa receptor inhibit the binding of fibrinogen to platelets regardless of which input stimuli activate the platelet and, thus, as demonstrated in the cyclic flow model, would be much more potent than aspirin as an antithrombotic agent. The cyclic flow model has been useful in predicting which agents are likely to be of benefit in clinical trials. (C) 1999 by the American College of Cardiology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:17:58